Insights by Samir Ounzain, Co-Founder and CEO of HAYA Therapeutics

🚀 How do you build a biotech company with global ambitions before the company even officially exists? In this exclusive Venture Leaders interview, Samir Ounzain, Co-Founder & CEO of HAYA Therapeutics, shares how a bold scientific vision evolved into one of Switzerland’s most promising clinical-stage biotechnology companies. From joining Venture Leaders Life Sciences in Boston while HAYA was still in its ideation phase to building a transatlantic company spanning Lausanne and San Diego, Samir opens up about biotech innovation, fundraising, international ecosystems, leadership, and why proximity to the right network can shape a company's future long before it raises capital. 🔬 Topics covered in this interview: • Biotech entrepreneurship & scaling • RNA therapeutics & the "dark genome" • Venture Leaders & international roadshows • Global fundraising & investor strategy • Building transatlantic biotech companies • Leadership across international teams • Strategic partnerships & ecosystem building • Founder mindset & long-term vision HAYA Therapeutics is developing a new generation of RNA-guided medicines by unlocking the therapeutic potential of the "dark genome", creating therapies for chronic diseases including heart failure, obesity, and metabolic disorders. 🌍 Venture Leaders, the Swiss National Startup Team, connects Switzerland’s most promising startups with top global investors and innovation hubs including Boston, New York, Silicon Valley, London, China, and more. 🎥 Watch the full interview and discover why Samir Ounzain says: “Think about building your global footprint before you need it. Proximity to the right ecosystem creates value long before you start raising capital.” 👉 Learn more about Venture Leaders: [www.ventureleaders.ch](http://www.ventureleaders.ch) #VentureLeaders #SwissStartups